Stanford researchers have invented a unified AI architecture that integrates foundational models (FMs) with AI techniques for efficient analysis of fMRI data in psychiatric disorders.
Stanford scientists designed a nanobody platform to inhibit the activity of granulysin, a protein that is often found in arterial plaque and released by T cells, to prevent the development of atherosclerosis such as heart attack and strokes.
Researchers at Stanford have discovered that nanobodies blocking amphiregulin (AREG) activity have the potential to impede the progression of early-stage atherosclerotic plaque lesions to advanced-stage fibroatheromas.
Stanford researchers have designed a nanobody platform to selectively block a key region on T cells found within arterial plaque, with the aim of preventing thrombotic complications and myocarditis.
Scientists in the Sunwoo Lab at Stanford have discovered that inhibition of the histone lysine demethylase KDMA2 can enhance the efficacy of immune checkpoint blockade therapies, like anti-PD-1.
Stanford researchers have developed a new methodology called transcript-informed single-cell CRISPR sequencing (TISCC-Seq), for the direct detection and phenotyping of genetic variants in a high-throughput manner.
Stanford researchers have developed a new phospho-responsive system to control protein secretion and surface expression of any tagged protein of interest. The invention enables complex control of multiple proteins.
There are several barriers to widespread use of CAR T-cell therapy. One of them is toxicity, primarily cytokine release syndrome (CRS) and neurologic toxicity, but also on-target off-tumor toxicity.
Stanford researchers have formulated a first in line framework called EcoTyper which systematically profiles the tumor microenvironment (TME) cell states in multiple solid tumor types, providing a platform for effective personalized cancer decisions.
Stanford researchers have developed a method that allows X-ray and CT imaging to achieve the same signal with two to three orders of magnitude less X-ray dosage.
Stanford scientists have discovered that bispecific antibodies can selectively bind cancer cells and block the CD47-SIRPα "don't eat me signal" to efficiently clear tumors with negligible toxicity.
A Stanford research team has patented methods that can prevent or reverse T cell exhaustion, thereby increasing the effectiveness of adoptive T cell therapies to fight cancer or chronic infections.
Researchers at Stanford have developed a nucleic acid amplification test to detect high-risk Epstein-Barr Virus (EBV) BALF2 variants in plasma to aid population-level screening for nasopharyngeal carcinoma (NPC).